Literature DB >> 31570849

PCSK9-lowering RNAi contender clears first phase III trial.

Asher Mullard.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31570849     DOI: 10.1038/d41573-019-00153-1

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  6 in total

1.  From methylene bridged diindole to carbonyl linked benzimidazoleindole: Development of potent and metabolically stable PCSK9 modulators.

Authors:  Haibo Xie; Ka Yang; Gabrielle N Winston-McPherson; Donnie S Stapleton; Mark P Keller; Alan D Attie; Kerry A Smith; Weiping Tang
Journal:  Eur J Med Chem       Date:  2020-08-04       Impact factor: 6.514

Review 2.  Circulating tumor cells as Trojan Horse for understanding, preventing, and treating cancer: a critical appraisal.

Authors:  Alexios-Fotios A Mentis; Petros D Grivas; Efthimios Dardiotis; Nicholas A Romas; Athanasios G Papavassiliou
Journal:  Cell Mol Life Sci       Date:  2020-04-24       Impact factor: 9.261

Review 3.  PNPLA3-A Potential Therapeutic Target for Personalized Treatment of Chronic Liver Disease.

Authors:  Xiaocheng Charlie Dong
Journal:  Front Med (Lausanne)       Date:  2019-12-17

4.  In Vivo Follow-Up of Gene Inhibition in Solid Tumors Using Peptide-Based Nanoparticles for siRNA Delivery.

Authors:  Isabel Ferreiro; Coralie Genevois; Karidia Konate; Eric Vivès; Prisca Boisguérin; Sébastien Deshayes; Franck Couillaud
Journal:  Pharmaceutics       Date:  2021-05-19       Impact factor: 6.321

Review 5.  Long Non-coding RNAs Mechanisms of Action in HIV-1 Modulation and the Identification of Novel Therapeutic Targets.

Authors:  Roslyn M Ray; Kevin V Morris
Journal:  Noncoding RNA       Date:  2020-03-13

Review 6.  The Role of Metabolic Lipases in the Pathogenesis and Management of Liver Disease.

Authors:  Matteo Tardelli; Francesca Virginia Bruschi; Michael Trauner
Journal:  Hepatology       Date:  2020-09       Impact factor: 17.425

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.